Abstract
More than 2 million new cases and over 600,000 breast cancer deaths were reported in 2018 worldwide. Out of these, 15 to 20% are Triple Negative Breast Cancer (TNBC), which lack all the three most commonly administered receptors, namely ER, PR, and Her2 amplification. Hence, TNBC is difficult to treat; and it has the highest five-year recurrence rate among breast cancer types. Currently, TNBC patients are treated with platinum-based chemotherapeutics, such as cisplatin. With the aggressive and metastatic nature of TNBC cells, it demands immediate, alternate treatments. Electrochemotherapy is a proven drug delivery practice in molecular medicine. The combination of electrical pulses (EP)with Cisplatin (CsP)is studied using Label-free quantitative proteomics to better understand action pathways. Cisplatin alone and cisplatin combined with Electroporation (EP+CsP) on MDA-MB-231, human TNBC cells were used for this purpose. The results indicate that EP + CsP significantly upregulated Mitochondrial ribosomes and significantly downregulated ribosomes and ubiquitin-mediated proteolysis. A total of 12 proteins were found downregulated among both ribosomes and ubiquitin-mediated proteolysis. A total of 29 proteins were upregulated among Ribosomes. Mitochondrial ribosomes upregulation indicates the DNA damage was done by cisplatin, and proteasome inhibitors are proven to function as novel anticancer compounds.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
